La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Madrigal Pharmaceuticals Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Bill Sibold
Amministratore delegato
US$32.9m
Compenso totale
Percentuale dello stipendio del CEO | 0.8% |
Mandato del CEO | less than a year |
Proprietà del CEO | n/a |
Durata media del management | less than a year |
Durata media del Consiglio di amministrazione | 8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Broker Revenue Forecasts For Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Are Surging Higher
Aug 09While Madrigal's Rezdiffra Impresses, Great Uncertainties Loom In MASH Market
Aug 08Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
Jun 09Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Apr 24Madrigal Wins The 'MASH Dash' And A Chance To Shape The Market Before GLP-1 Challenge
Mar 15Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
Feb 07Calculating The Intrinsic Value Of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Dec 20We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Aug 05Madrigal: Buy And Hoard Before Q4 Data Readout
Aug 04Madrigal cut to Neutral at B. Riley on concerns over upcoming NASH readout
Jul 08Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Could Be 45% Below Their Intrinsic Value Estimate
May 11Madrigal: NASH Data In Q4 Is The Key
Apr 19We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Feb 24Madrigal: Delayed NASH Data Is Positive But Real Tests Are Still To Come
Jan 31Madrigal: Powerful Catalyst Approaching
Jan 09We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Nov 08We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate
Jul 26Madrigal Pharmaceuticals: Leading The NASH Innovation
May 05Here's Why We're Watching Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Situation
Apr 12We Think Madrigal Pharmaceuticals (NASDAQ:MDGL) Can Afford To Drive Business Growth
Dec 28Madrigal Pharma: A Look At The Early MAESTRO Trial Data
Nov 27Madrigal Pharmaceuticals (MDGL) Presents At AASLD 2020 Conference- Slideshow
Nov 17Madrigal Pharmaceuticals EPS misses by $0.40
Nov 05Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$510m |
Mar 31 2024 | n/a | n/a | -US$444m |
Dec 31 2023 | US$33m | US$275k | -US$374m |
Compensazione vs Mercato: La retribuzione totale di Bill ($USD 32.87M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.39M ).
Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Bill con le performance aziendali.
AMMINISTRATORE DELEGATO
Bill Sibold (58 yo)
less than a year
Mandato
US$32,871,801
Compensazione
Mr. William J. Sibold, also known as Bill, serves as Chief Executive Officer, President and Director at Madrigal Pharmaceuticals, Inc. since September 8, 2023. Mr. Sibold joined Madrigal Pharmaceuticals, I...
Gruppo dirigente
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | less than a year | US$32.87m | Nessun dato | |
Founder | 12.9yrs | US$6.93m | 5.02% $ 279.2m | |
Chief Commercial Officer | less than a year | US$3.14m | Nessun dato | |
CFO & Senior VP | less than a year | Nessun dato | Nessun dato | |
Chief Information Officer | less than a year | Nessun dato | Nessun dato | |
Chief Investor Relations Officer | less than a year | Nessun dato | Nessun dato | |
Chief Compliance Office & General Counsel | no data | Nessun dato | Nessun dato | |
Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
Senior Vice President of Clinical & Technical Operations | no data | Nessun dato | Nessun dato | |
Senior Vice President of Clinical Management | no data | Nessun dato | Nessun dato | |
Chief Pharmaceutical Development Officer | 3yrs | Nessun dato | 0.025% $ 1.4m | |
Senior Vice President of Global Medical Affairs | 2.8yrs | Nessun dato | Nessun dato |
0.8yrs
Durata media
60yo
Età media
Gestione esperta: Il team dirigenziale di MDGL non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
CEO, President & Director | less than a year | US$32.87m | Nessun dato | |
Founder | 8.1yrs | US$6.93m | 5.02% $ 279.2m | |
Independent Lead Director | 8.1yrs | US$65.00k | 1.78% $ 98.8m | |
Independent Director | 8.1yrs | US$77.50k | 0.0055% $ 307.0k | |
Independent Chairman of the Board | 1.2yrs | US$33.75k | 0.011% $ 614.1k | |
Director | 8.1yrs | US$9.80m | 4.37% $ 243.0m | |
Independent Director | 8yrs | US$62.50k | 0.047% $ 2.6m | |
Independent Director | 5.2yrs | US$57.50k | 0.0055% $ 307.0k | |
Independent Director | 1.2yrs | US$27.50k | 0.011% $ 614.1k |
8.0yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MDGL sono considerati esperti (durata media dell'incarico 8 anni).